Vor Biopharma Inc. Fair Value, Assets, Level 2 to Level 1 Transfers, Amount
Vor Biopharma Inc. (VOR) had Fair Value, Assets, Level 2 to Level 1 Transfers, Amount of $0 as of 2021-03-31, per its 10-Q filed 2021-05-06.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount · last filed 2021-08-09
- 2021-03-31: Fair Value, Assets, Level 2 to Level 1 Transfers, Amount $0.00.
- 2020-12-31: Fair Value, Assets, Level 2 to Level 1 Transfers, Amount $0.00.
| Period end | Fair Value, Assets, Level 2 to Level 1 Transfers, Amount |
|---|---|
| 2021-03-31 | $0.00 10-Q · filed 2021-05-06 |
| 2020-12-31 | $0.00 10-Q · filed 2021-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |